Therapeutic advances in medical oncology · 2026
Second-line oxaliplatin reintroduction or paclitaxel-ramucirumab in metastatic gastroesophageal cancer: a population-based study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Siegerink Sebastiaan N, Kuijper Steven C, van den Ende Tom, Verhoeven Rob H A, Elias Sjoerd G, Mohammad Nadia Haj, Slingerland Marije, Derks Sarah, van Laarhoven Hanneke W M
Аннотация
BACKGROUND: Reintroduction of oxaliplatin after first-line treatment might preserve treatment lines and could improve overall survival.
OBJECTIVES: We investigate whether oxaliplatin reintroduction (OXR) or paclitaxel-ramucirumab (PR) is preferred in terms of overall survival for patients with gastroesophageal adenocarcinoma who have disease progression on first-line treatment.
DESIGN: We performed a target trial emulation with a propensity-scored inverse probability weighting approach to resemble a randomized controlled trial.
METHODS: Observational data was retrieved from the Netherlands Cancer Registry between 2015 and 2018, with a maximum follow-up until 2022. Patients were included if they received a fluoropyrimidine with oxaliplatin in first-line and as subsequent treatment OXR or PR. There was at least 6 months between planned discontinuation of oxaliplatin and disease progression.
RESULTS: We included 129 patients in our model and the weighted cohort was well balanced between the two groups. No statistically significant difference in overall survival was observed between treatment groups (HR: 0.76, 95% CI: 0.3-1.5; p = 0.36). Median overall survival was 9.2 months (95% CI: 3.7-25.1) for OXR and 7.9 months (95% CI: 2.8-11.5) for PR (p = 0.38). Exploratory subgroup analysis did not reach statistical significance. Patients in the OXR-group more often received one or more additional treatment lines, including second-line PR, than patients in the PR group, 47.7% versus 23.3%, respectively.
CONCLUSION: OXR following prolonged response to first-line treatment was associated with similar overall survival compared with PR. In the absence of a demonstrated survival benefit for either treatment, these results propose oxaliplatin reintroduction as a potential option in selected patients.
OBJECTIVES: We investigate whether oxaliplatin reintroduction (OXR) or paclitaxel-ramucirumab (PR) is preferred in terms of overall survival for patients with gastroesophageal adenocarcinoma who have disease progression on first-line treatment.
DESIGN: We performed a target trial emulation with a propensity-scored inverse probability weighting approach to resemble a randomized controlled trial.
METHODS: Observational data was retrieved from the Netherlands Cancer Registry between 2015 and 2018, with a maximum follow-up until 2022. Patients were included if they received a fluoropyrimidine with oxaliplatin in first-line and as subsequent treatment OXR or PR. There was at least 6 months between planned discontinuation of oxaliplatin and disease progression.
RESULTS: We included 129 patients in our model and the weighted cohort was well balanced between the two groups. No statistically significant difference in overall survival was observed between treatment groups (HR: 0.76, 95% CI: 0.3-1.5; p = 0.36). Median overall survival was 9.2 months (95% CI: 3.7-25.1) for OXR and 7.9 months (95% CI: 2.8-11.5) for PR (p = 0.38). Exploratory subgroup analysis did not reach statistical significance. Patients in the OXR-group more often received one or more additional treatment lines, including second-line PR, than patients in the PR group, 47.7% versus 23.3%, respectively.
CONCLUSION: OXR following prolonged response to first-line treatment was associated with similar overall survival compared with PR. In the absence of a demonstrated survival benefit for either treatment, these results propose oxaliplatin reintroduction as a potential option in selected patients.